Sarvajna Dwivedi

Co-Founder & Chief Scientific Officer, Pearl Therapeutics
Sarvajna Dwivedi

Sarvajna Dwivedi

Co-Founder & Chief Scientific Officer, Pearl Therapeutics

Biography

Sarvajna Dwivedi has extensive experience in drug development at GSK, Dura Pharmaceuticals Inc. (Dura), Alkermes plc. (Alkermes), and Nektar Therapeutics (Nektar). He was involved in the development of over 40 molecules in various therapeutic classes and dosage forms from discovery to commercialization. At Nektar, he was the Director of Product Development, responsible for new product identification, design, planning, and development efforts. At Alkermes, he was the Director of Delivery Systems, responsible for the engineering and development of inhalers for multiple products. At Dura, Dr. Dwivedi led and managed formulation design and development efforts for various Spiros programmes. Earlier, at GSK, Dr. Dwivedi was involved in the development, manufacturing, and approval of Flovent® Diskhaler, Serevent® Diskus, Advair®Diskus, Relenza® Diskhaler, and Ventolin® Evohaler.

In addition to his product development experience, Dr. Dwivedi has led and conducted technical due diligence efforts for in-licensing, out-licensing and acquisition opportunities. Dr. Dwivedi holds MSc and PhD degrees in Pharmaceutical Sciences from the University of British Columbia, Canada and M.Pharm. & B.Pharm.(Hons) from Banaras Hindu University, Varanasi, India.